既往SARS-CoV-2感染对再感染的保护作用:系统综述与荟萃分析
该研究系统检索截至2022年9月31日发表的回顾性与前瞻性队列研究及检测阴性病例对照研究,纳入19个国家的65项研究,用贝叶斯荟萃回归估计既往感染对不同变异株再感染、症状性疾病和重症的保护效力。结果显示奥密克戎BA.1再感染保护为45.3%,重症保护对所有变异株均大于78%,再感染保护随时间下降。
要点
- 既往感染对奥密克戎BA.1再感染保护为45.3%,对症状性疾病保护为44.0%。
- 对所有变异株的重症保护合并效力均大于78%。
- 再感染保护随时间下降,奥密克戎BA.1在40周时降至36.1%。
核心结论
- 既往感染对奥密克戎前变异株再感染的保护很高,40周后仍保持较高水平。
- 奥密克戎BA.1再感染保护明显较低,且随时间下降更快。
- 所有变异株的重症保护均较高。
- 评估未来疾病负担、接种时机和免疫状态相关政策时,应将既往感染获得的免疫与疫苗保护一并考虑。
研究设计与样本
- 系统综述与荟萃分析,检索截至2022年9月31日发表的回顾性和前瞻性队列研究及检测阴性病例对照研究。
- 共纳入来自19个不同国家的65项研究。
- 按结局(感染、症状性疾病、重症)、变异株和感染后时间进行荟萃分析,并用贝叶斯荟萃回归估计合并保护效力。
- 偏倚风险评估使用美国国立卫生研究院质量评估工具,系统综述符合PRISMA并注册于PROSPERO(编号CRD42022303850)。
主要发现
- 对奥密克戎BA.1再感染的合并效力为45.3%(95%不确定性区间17.3-76.1),对奥密克戎BA.1症状性疾病的合并效力为44.0%(26.5-65.0)。
- 对所有变异株(包括奥密克戎BA.1)的重症(住院和死亡)合并效力均大于78%。
- 对祖先、alpha和delta变异株再感染的保护随时间下降,40周时仍为78.6%(49.8-93.6)。
- 对奥密克戎BA.1再感染的保护下降更快,40周时估计为36.1%(24.4-51.3)。
- 40周时对重症的保护仍较高:祖先、alpha和delta变异株为90.2%(69.7-97.5),奥密克戎BA.1为88.9%(84.7-90.9)。
临床怎么用
- 评估未来COVID-19疾病负担、提供个体接种时机指导、设计基于免疫状态强制接种或限制进入高风险场所(如旅行和高 occupancy 室内环境)的政策时,应将既往感染获得的免疫与疫苗保护一并权衡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Understanding the level and characteristics of protection from past SARS-CoV-2 infection against subsequent re-infection, symptomatic COVID-19 disease, and severe disease is essential for predicting future potential disease burden, for designing policies that restrict travel or access to venues where there is a high risk of transmission, and for informing choices about when to receive vaccine doses. We aimed to systematically synthesise studies to estimate protection from past infection by variant, and where data allow, by time since infection. METHODS: In this systematic review and meta-analysis, we identified, reviewed, and extracted from the scientific literature retrospective and prospective cohort studies and test-negative case-control studies published from inception up to Sept 31, 2022, that estimated the reduction in risk of COVID-19 among individuals with a past SARS-CoV-2 infection in comparison to those without a previous infection. We meta-analysed the effectiveness of past infection by outcome (infection, symptomatic disease, and severe disease), variant, and time since infection. We ran a Bayesian meta-regression to estimate the pooled estimates of protection. Risk-of-bias assessment was evaluated using the National Institutes of Health quality-assessment tools. The systematic review was PRISMA compliant and was registered with PROSPERO (number CRD42022303850). FINDINGS: We identified a total of 65 studies from 19 different countries. Our meta-analyses showed that protection from past infection and any symptomatic disease was high for ancestral, alpha, beta, and delta variants, but was substantially lower for the omicron BA.1 variant. Pooled effectiveness against re-infection by the omicron BA.1 variant was 45·3% (95% uncertainty interval [UI] 17·3-76·1) and 44·0% (26·5-65·0) against omicron BA.1 symptomatic disease. Mean pooled effectiveness was greater than 78% against severe disease (hospitalisation and death) for all variants, including omicron BA.1. Protection from re-infection from ancestral, alpha, and delta variants declined over time but remained at 78·6% (49·8-93·6) at 40 weeks. Protection against re-infection by the omicron BA.1 variant declined more rapidly and was estimated at 36·1% (24·4-51·3) at 40 weeks. On the other hand, protection against severe disease remained high for all variants, with 90·2% (69·7-97·5) for ancestral, alpha, and delta variants, and 88·9% (84·7-90·9) for omicron BA.1 at 40 weeks. INTERPRETATION: Protection from past infection against re-infection from pre-omicron variants was very high and remained high even after 40 weeks. Protection was substantially lower for the omicron BA.1 variant and declined more rapidly over time than protection against previous variants. Protection from severe disease was high for all variants. The immunity conferred by past infection should be weighed alongside protection from vaccination when assessing future disease burden from COVID-19, providing guidance on when individuals should be vaccinated, and designing policies that mandate vaccination for workers or restrict access, on the basis of immune status, to settings where the risk of transmission is high, such as travel and high-occupancy indoor settings. FUNDING: Bill & Melinda Gates Foundation, J Stanton, T Gillespie, and J and E Nordstrom.
引用
- Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet. 2023. PMID: 36930674. doi:10.1016/S0140-6736(22)02465-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。